To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors

Summary

Patients with advanced tumors diagnosed histologically or cytologically at the study center who were refractory to standard therapy or had relapsed received XNW5004 tablets

Timeline

Start

2021-08-03

Primary completion

2025-08-30

Completion

2025-08-30

Drugs

Indications